Trial · NCT00090870
PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
NCT00090870, Phase 2, Terminated, Medical University of South Carolina; results first posted 2018-07-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer. Trials, record NCT00090870. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00090870
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
- NCT number
- NCT00090870
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 10 participants, actual
- Lead sponsor
- Medical University of South Carolina
- Conditions
- Kidney Cancer
- Interventions
- PEG-interferon alfa-2b, GM-CSF, thalidomide
- First posted
- 2004-09-08
- Last updated
- 2018-07-12
- Results first posted
- 2018-07-12
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Response Rate | while on study, every 4 cycles; while off study, every 3 months for 1 year, then every 6 month for 2 years, then every year | To define the response rate in metastatic renal cell carcinoma patients receiving Peg-Intron, GM-CSF and thalidomide |
| Secondary | Duration of Response | time from registration to the time of progressive disease among patients who achieve at least a partial response to treatment. | |
| Secondary | Frequency of Adverse Events Assessed by NCI CTC Version 2 | From the first day of treatment until the end of treatment visit, an average of 6 months | |
| Secondary | Progression-free Survival | From registration until diease progression or death, whichever comes first. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Response Rate | while on study, every 4 cycles; while off study, every 3 months for 1 year, then every 6 month for 2 years, then every year | Data for this endpoint was not collected | ||
| SECONDARY | Duration of Response | time from registration to the time of progressive disease among patients who achieve at least a partial response to treatment. | Data for this endpoint was not collected | ||
| SECONDARY | Frequency of Adverse Events Assessed by NCI CTC Version 2 | From the first day of treatment until the end of treatment visit, an average of 6 months | Data for this endpoint was not collected | ||
| SECONDARY | Progression-free Survival | From registration until diease progression or death, whichever comes first. | Data for this endpoint was not collected |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | PEG-Intron, BM-CSF and Thalidomide | 10 | |
| Overall Study | COMPLETED | PEG-Intron, BM-CSF and Thalidomide | 10 | |
| Overall Study | NOT COMPLETED | PEG-Intron, BM-CSF and Thalidomide | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | PEG-Intron, BM-CSF and Thalidomide | ||
| Total, other adverse events | PEG-Intron, BM-CSF and Thalidomide | 0 | 0 |
| Total, serious adverse events | PEG-Intron, BM-CSF and Thalidomide | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00090870
GET https://conductscience.org/api/trials/v1/NCT00090870/registered